Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

7.180 -0.130 (-1.78%)
Delayed Quote Updated: 11:59 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million... 
Via Benzinga
News headline image
Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump ↗
Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
35 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Here's Why Ocular Therapeutix Stock Is Sinking Today ↗
The company's experimental dry-eye treatment produced some disappointing clinical trial results. 
Via The Motley Fool
News headline image
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Monday ↗
Barclays reduced the price target for The Walt Disney Company (NYSE: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
News headline image
46 Biggest Movers From Yesterday ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’... 
Via Benzinga
News headline image
Why Are Ocular Therapeutix Shares Trading Higher Today? ↗
The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
28 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
This Exciting Biopharma Could Earn You 55% in 12 Months ↗
When patients see more clearly, so too should investors. 
Via The Motley Fool
News headline image
4 Reasons I Just Bought Ocular Therapeutix Stock ↗
This company's drug delivery technology just isn't getting the appreciation it deserves right now. 
Via The Motley Fool
News headline image
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases ↗
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Sensus Healthcare (NASDAQ:SRTS) ... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 9, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.